SLC19A1 and bladder transitional cell carcinoma: Further, based on our present findings, RFC overexpression implies that urothelial bladder carcinomas would be intrinsically more sensitive to antifolates whereas non-urothelial carcinomas would show a less favorable response to antifolate chemotherapy.